Skip to main content

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

Video, ASCO Highlights
Videos
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.

Related Items

Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024 Vol 17, No 2
ASCO Highlights
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024 Vol 17, No 2
ASCO Highlights
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
By Patricia Stewart
TOP - July 2022 Vol 15, No 4
Rectal Cancer, ASCO Highlights
Ibrutinib Added to Standard-of-Care Therapy Improves Progression-Free Survival in Older Patients with MCL
By William King
TOP - July 2022 Vol 15, No 4
ASCO Highlights